Who makes Low-dose Pazopanib in Pediatric Cohort?

Low-dose Pazopanib in Pediatric Cohort is developed by University Hospital, Bordeaux.

What development phase is Low-dose Pazopanib in Pediatric Cohort in?

Low-dose Pazopanib in Pediatric Cohort is in Phase 1.

Last reviewed 2026-04-20 · How we verify

Low-dose Pazopanib in Pediatric Cohort

University Hospital, Bordeaux · Phase 1 active Small molecule Quality 0/100

At a glance

Generic name	Low-dose Pazopanib in Pediatric Cohort
Sponsor	University Hospital, Bordeaux
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Spartalizumab and Low-dose PAzopanib in Refractory or Relapsed Solid TumOrs of Pediatric and Adults (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Low-dose Pazopanib in Pediatric Cohort CI brief — competitive landscape report
Low-dose Pazopanib in Pediatric Cohort updates RSS · CI watch RSS
University Hospital, Bordeaux portfolio CI